Literature DB >> 25027296

The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Sosipatros A Boikos1, Constantine A Stratakis.   

Abstract

About 10-15 % of adult gastrointestinal stromal tumors (GISTs) and 85 % of pediatric GISTs do not have mutations in the KIT or PDGFRA genes and are generally classified as KIT/PDGFRA wild type (WT). Recent studies have shown that this group of KIT/PDGFRA WT GISTs is quite heterogeneous in terms of clinical phenotype, genetic etiology, and molecular pathways. Succinate dehydrogenase subunit (SDH)-deficient GISTs, which include tumors that are part of multiple endocrine neoplasia syndromes, are the newest group of KIT/PDGFRA WT GIST to be molecularly elucidated. This review aims to describe the different genetic subgroups of KIT/PDGFRA WT GIST, with a special focus on the SDH-deficient GIST.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25027296      PMCID: PMC4729312          DOI: 10.1007/s12020-014-0346-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  69 in total

1.  No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma.

Authors:  M Montani; A M Schmitt; S Schmid; T Locher; P Saremaslani; P U Heitz; P Komminoth; A Perren
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

2.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

3.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors:  Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

4.  MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.

Authors:  Won Kyu Kim; Misun Park; Young-Kook Kim; You Kwon Tae; Han-Kwang Yang; Jae Myun Lee; Hoguen Kim
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

5.  Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications.

Authors:  Jerzy Lasota; Zengfeng Wang; Su Young Kim; Lee Helman; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

6.  Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age.

Authors:  Markku Miettinen; Zeng-Feng Wang; Maarit Sarlomo-Rikala; Czeslaw Osuch; Piotr Rutkowski; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2011-11       Impact factor: 6.394

7.  Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?

Authors:  Paraskevi Xekouki; Karel Pacak; Madson Almeida; Christopher A Wassif; Pierre Rustin; Maria Nesterova; Maria de la Luz Sierra; Joey Matro; Evan Ball; Monalisa Azevedo; Anelia Horvath; Charalampos Lyssikatos; Martha Quezado; Nicholas Patronas; Barbara Ferrando; Barbara Pasini; Aristides Lytras; George Tolis; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

8.  Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect.

Authors:  Barbara Pasini; Ludmila Matyakhina; Thalia Bei; Michael Muchow; Sosipatros Boikos; Barbara Ferrando; J Aidan Carney; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2007-06-12       Impact factor: 5.958

9.  Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.

Authors:  Eric P Kleinbaum; Alexander J F Lazar; Elena Tamborini; John C Mcauliffe; Pamela B Sylvestre; Thomas D Sunnenberg; Louise Strong; Lei L Chen; Haesun Choi; Robert S Benjamin; Wei Zhang; Jonathan C Trent
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

10.  Aorticopulmonary paraganglioma and gastric leiomyoblastoma in a young woman.

Authors:  M P Grace; G Batist; W R Grace; J F Gillooley
Journal:  Am J Med       Date:  1981-06       Impact factor: 4.965

View more
  11 in total

1.  Carney triad can be (rarely) associated with germline succinate dehydrogenase defects.

Authors:  Sosipatros A Boikos; Paraskevi Xekouki; Elena Fumagalli; Fabio R Faucz; Margarita Raygada; Eva Szarek; Evan Ball; Su Young Kim; Markku Miettinen; Lee J Helman; J Aidan Carney; Karel Pacak; Constantine A Stratakis
Journal:  Eur J Hum Genet       Date:  2015-07-15       Impact factor: 4.246

Review 2.  Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome.

Authors:  Nikolaos Settas; Fabio R Faucz; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2017-07-21       Impact factor: 4.102

3.  The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?

Authors:  Roman Groisberg; Vivek Subbiah
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-13

4.  Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Authors:  Massimo Milione; Patrick Maisonneuve; Alessio Pellegrinelli; Sara Pusceddu; Giovanni Centonze; Francesca Dominoni; Cecilia Brambilla; Manila Rubino; Antongiulio Faggiano; Roberto Buzzoni; Laura Concas; Luca Giacomelli; Jorgelina Coppa; Vincenzo Mazzaferro; Filippo de Braud
Journal:  Endocrine       Date:  2016-11-30       Impact factor: 3.633

Review 5.  Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.

Authors:  Hani J Alturkmani; Ziyan Y Pessetto; Andrew K Godwin
Journal:  Expert Opin Investig Drugs       Date:  2015-06-22       Impact factor: 6.206

6.  Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome.

Authors:  Liping Lou; Wendi Zhang; Jun Li; Yu Wang
Journal:  Cancer Manag Res       Date:  2020-10-12       Impact factor: 3.989

7.  Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question.

Authors:  Bo-Ru Lai; Yu-Tung Wu; Yung-Chia Kuo; Hung-Chih Hsu; Jen-Shi Chen; Tse-Ching Chen; Ren-Chin Wu; Cheng-Tang Chiu; Chun-Nan Yeh; Ta-Sen Yeh
Journal:  Oncotarget       Date:  2016-12-13

8.  KIT mutation in a naïve succinate dehydrogenase-deficient gastric GIST.

Authors:  Iva Brcic; Karl Kashofer; Daniela Skone; Bernadette Liegl-Atzwanger
Journal:  Genes Chromosomes Cancer       Date:  2019-06-10       Impact factor: 5.006

9.  Risk-Related Genes and Associated Signaling Pathways of Gastrointestinal Stromal Tumors.

Authors:  Fulai Gao; Jiaqi Wang; Changjuan Li; Changshun Xie; Miao Su; Chunyan Zou; Xiaoli Xie; Dongqiang Zhao
Journal:  Int J Gen Med       Date:  2022-04-08

Review 10.  Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Authors:  Lin Mei; Wei Du; Michael Idowu; Margaret von Mehren; Sosipatros A Boikos
Journal:  Front Oncol       Date:  2018-05-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.